Physician profile
Stacey Moore
NPI 1275684268
$975.10
in general payments reported to CMS, 2019-2025
13 companies · $50.21 in 2025
The $50.21 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $530 · 2023: $200 · 2024: $33.21 · 2025: $50.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.37 | 2021-2024 | |
| Therapeuticsmd, INC. | $152.21 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $126.18 | 2022-2023 | |
| Mylan Pharmaceuticals INC. | $87.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $82.21 | 2022-2025 | Andexxa, Breztri |
| Pfizer INC. | $62.80 | 2022-2023 | |
| Exeltis, USA INC. | $54.77 | 2022-2023 | Tyblume |
| Astellas Pharma US INC | $52.55 | 2021-2025 | Veozah |
| Myovant Sciences INC. | $36.85 | 2021-2022 | |
| Gynesonics, INC. | $34.74 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $31.55 | 2021 | |
| Sumitomo Pharma America, INC. | $20.66 | 2023 | Myfembree |
| Agile Therapeutics, INC. | $18.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.